PVLA (Palvella Therapeutics) Insider Ownership: 2.74 % (As of Sep. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PVLA Palvella Therapeutics Inc PVLA
14 GF Score
Price $152.15
! 2 Warning Signs
View Full Analysis

What is Palvella Therapeutics Insider Ownership?

Palvella Therapeutics PVLA +1.18% 14 Insider Ownership is 2.74 % as of Sep. 02, 2026. GuruFocus rates PVLA with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Palvella Therapeutics's insider ownership is 2.74%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Palvella Therapeutics's Institutional Ownership is 97.91%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Palvella Therapeutics's Float Percentage Of Total Shares Outstanding is 88.40%.

Palvella Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Palvella Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Palvella Therapeutics Insider Ownership Chart

Palvella Therapeutics Historical Data

The historical data trend for Palvella Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 3.49 3.49 3.49 3.49 3.26 3.26 2.76 2.74 2.74 2.74
PVLA
14GF Score
Palvella Therapeutics Inc PVLA
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Palvella Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 2.74 % mean?
Palvella Therapeutics (PVLA) has a Insider Ownership of 2.74 % as of Sep. 02, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Palvella Therapeutics and its competitors.
Is Palvella Therapeutics' Insider Ownership too high?
Palvella Therapeutics' current Insider Ownership is 2.74 %. Overall, Palvella Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Palvella Therapeutics' Insider Ownership compare to AUPH and URGN?
Palvella Therapeutics' Insider Ownership of 2.74 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Palvella Therapeutics and its competitors. Palvella Therapeutics's current Insider Ownership is 2.74 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Palvella Therapeutics stock overvalued right now?
Palvella Therapeutics (PVLA) has a current Insider Ownership of 2.74 %. The current Insider Ownership is 2.74 %. Palvella Therapeutics' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Palvella Therapeutics (PVLA), the current Insider Ownership is 2.74 % as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Palvella Therapeutics Business Description

Other Exchanges PI6:Germany
Address 353 W. Lancaster Avenue, Suite 200, Wayne, PA, USA, 19087
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
14GF Score

Get the complete analysis for PVLA

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$152.15
Price